• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Arcus Biosciences Inc.

    10/30/25 6:21:09 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCUS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001422996
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Arcus Biosciences, Inc.
    SEC File Number
    001-38419
    Address of Issuer
    3928 Point Eden Way
    Hayward
    CALIFORNIA
    94545
    Phone
    1-510-694-6200
    Name of Person for Whose Account the Securities are To Be Sold
    Juan Jaen
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A Common Stock
    Goldman Sachs & Co. LLC
    200 West Street
    New York � NY � 10282
    117323682.8710797353610/30/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A Common Stock05/29/2015Acquired from issuer in private transactionThe IssuerCheckbox not checked117305/29/2015None

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    The Juan Carlos Jaen and Anita Galeana 2000 Trust
    3928 Point Eden Way
    Hayward � CA � 94545
    Class A Common Stock10/28/202519019383944.16
    The Juan Carlos Jaen and Anita Galeana 2000 Trust
    3928 Point Eden Way
    Hayward � CA � 94545
    Class A Common Stock10/29/2025766671600791.63
    The Juan Carlos Jaen and Anita Galeana 2000 Trust
    3928 Point Eden Way
    Hayward � CA � 94545
    Class A Common Stock10/29/2025117325844.94
    The Juan Carlos Jaen and Anita Galeana 2000 Trust
    3928 Point Eden Way
    Hayward � CA � 94545
    Class A Common Stock10/30/2025314163817.27

    144: Remarks and Signature

    Remarks
    The sales of shares set forth herein are made in connection with a selling plan dated 8/12/2024, that is intended to comply with Rule 10b5-1(c). All shares to be sold by the Juan Carlos Jaen and Anita Galeana 2000 Trust.
    Date of Notice
    10/30/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/12/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Goldman Sachs & Co. LLC on behalf of Juan Jaen

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RCUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCUS

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    More analyst ratings

    $RCUS
    SEC Filings

    View All

    SEC Form 424B5 filed by Arcus Biosciences Inc.

    424B5 - Arcus Biosciences, Inc. (0001724521) (Filer)

    10/31/25 4:22:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcus Biosciences Inc.

    144 - Arcus Biosciences, Inc. (0001724521) (Subject)

    10/30/25 6:21:09 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Arcus Biosciences Inc.

    424B5 - Arcus Biosciences, Inc. (0001724521) (Filer)

    10/30/25 4:57:57 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Leadership Updates

    Live Leadership Updates

    View All

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

    2/11/25 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

    Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

    1/21/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

    8/24/22 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Financials

    Live finance-specific insights

    View All

    Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

    Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly Arcus will host a conference call to discuss these data at 5:0

    6/1/25 10:45:00 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

    Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

    5/6/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

    New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

    4/23/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcus Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

    2/26/25 7:16:55 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

    H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

    10/21/24 7:58:13 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Arcus Biosciences with a new price target

    Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

    10/8/24 7:34:04 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $18.25 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences has granted the underwriters a 30-day option to purch

    10/30/25 11:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Announces Commencement of Public Offering of Common Stock

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may b

    10/30/25 4:01:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

    Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney cancer Multiple readouts from the ARC-20 study of casdatifan are expected in 2026, including additional analyses of the late-line monotherapy cohorts early in 2026, followed by more mature data from the casdatifan plus cabozantinib cohort in mid-2026 and initial data from the early-line cohorts in the second half of 2026 Domvanalimab plus zimberelimab and chemotherapy showed a median overall survival (OS) of 26.7 months in Arm A1 of the Phase 2 EDGE-Gastric study (overall

    10/28/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Jaen Juan C. sold $2,010,578 worth of shares (96,859 units at $20.76) (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    10/30/25 8:49:09 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goeltz Ii Robert C. sold $100,000 worth of shares (5,000 units at $20.00), decreasing direct ownership by 5% to 92,138 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    10/29/25 8:54:18 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Jarrett Jennifer exercised 50,292 shares at a strike of $1.23 and sold $750,412 worth of shares (50,292 units at $14.92) (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    10/8/25 7:08:18 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:06:05 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:05:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/20/25 7:42:29 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RCUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    11/12/24 9:50:12 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

    SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    10/17/24 11:31:06 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care